Related Experiment Video
Updated: May 25, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no
Abstract:
Erlotinib-an oral tyrosine kinase inhibitor (tki) of the epidermal growth factor receptor (egfr)-has commonly been used as a therapeutic option in metastatic non-small-cell lung cancer (nsclc) patients in the second- or third-line treatment setting. A mutation in the EGFR gene (EGFR M+) confers an increased response to this class of drugs. In the first-line setting, use of tkis is restricted to patients having a mutation. The importance of this biomarker has been questioned in subsequent treatment lines.Here, we report a case showing a positive response to erlotinib treatment in the second-line setting. The patient, an elderly male smoker with stage iv nsclc, had a tumour that was EGFR mutation-negative (wild-type EGFR). Based on this clinical case, we discuss the controversy concerning the need for, and impact of, testing for EGFR mutation after first-line treatment.
Insights
Erlotinib showed positive response in a metastatic non-small-cell lung cancer patient with wild-type EGFR. This case highlights the ongoing debate on EGFR mutation testing
Area of Science:
- Oncology
- Pharmacology
Background:
- Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is a standard treatment for metastatic non-small-cell lung cancer (NSCLC).
- EGFR mutations predict response to TKIs, particularly in the first-line setting, but their importance in later lines is debated.
Purpose of the Study:
- To present a case of a positive response to erlotinib in a second-line NSCLC treatment setting.
- To discuss the clinical implications of EGFR mutation testing in NSCLC patients after first-line therapy.
Main Methods:
- Case report of an elderly male smoker with stage IV NSCLC.
- Treatment with erlotinib in the second-line setting despite wild-type EGFR status.
Main Results:
- The patient, with wild-type EGFR, demonstrated a positive response to erlotinib.
- This outcome challenges the established role of EGFR mutation status in guiding second-line TKI therapy.
Conclusions:
- EGFR mutation testing may still hold relevance beyond first-line treatment in NSCLC.
- Further investigation is warranted to clarify the role of EGFR biomarkers in subsequent treatment lines for NSCLC.
